A first-in-class inhibitor, MLN4924 (pevonedistat), induces cell-cycle arrest, senescence, and apoptosis in human renal cell carcinoma by suppressing UBE2M-dependent neddylation modification.
Bo XuYuyou DengRan BiHaoran GuoChang ShuNeelam Kumari ShahJunliang ChangGuanchen LiuYujun DuWei WeiChunxi WangPublished in: Cancer chemotherapy and pharmacology (2018)
We concluded that MLN4924 induces apoptosis and cell cycle arrest. These findings implied that MLN4924 provides a novel strategy for the treatment of RCC.